Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose CM maintenance in early breast cancer
NCT00022516Phase 3Completed
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Nov 2000
- Primary completion
- Jan 2015
- Modality
- Orthosteric Ligands
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of cyclophosphamide and methotrexate in breast cancer (2 arms), sponsored by ETOP IBCSG Partners Foundation. Primary endpoint: Disease-free Survival at 5 years. Started Nov 2000; status: completed.
02
Drugs
cyclophosphamidemethotrexate
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00022516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00022516.